Managing Director, D.E. Shaw and Co., L.P.
Medical College of Wisconsin director of research commercialization
Director, Life Sciences Institute, University of Michigan
Founder and CEO of Brooks Bell Inc.
Director, Silicon Flatirons Centers' Entrepreneurship Initiative
CEO and co-founder of BoostSuite
Chief Strategy and Innovation Officer, Blue Cross and Blue Shield of North Carolina
Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP) is a rare, progressive and fatal neurodegenerative disease that affects approximately 8,000 patients worldwide. Based on results from a pivotal 18-month placebo controlled clinical trial featuring an 18-month follow-on study, Pfizer’s tafamidis (Vyndaqel) has proven its effectiveness in delaying peripheral neurologic impairment. In giving the drug its green light, the European Commission made tafamidis the world’s first approved medication for TTR-FAP. More information and online registration is available here.